Objectives: The increase in infections caused by drug-resistant ESBL-producing Enterobacteriaceae (ESBL-ENT) is a global concern. The characteristics and outcomes of patients infected with ESBL-ENT were examined in a pooled analysis of Phase 3 clinical trials of ceftolozane/tazobactam in patients with complicated urinary tract infections (ASPECT-cUTI) and complicated intra-abdominal infections (ASPECT-cIAI).
Introduction
Infections caused by ESBL-producing Enterobacteriaceae (ESBL-ENT), particularly Escherichia coli and Klebsiella pneumoniae, are on the increase. 1 Resistance among ESBL producers extends not only to b-lactams (BL) including penicillin and third-generation cephalosporins but also to aminoglycosides and fluoroquinolones. 2, 3 Carbapenems remain the preferred treatment for severe infections caused by ESBL producers. 4, 5 New antibiotics, such as BL/b-lactamase inhibitor (BLI) combinations, may be useful carbapenem-sparing options against ESBL-ENT.
Ceftolozane/tazobactam is a novel BL/BLI combination approved for the treatment of complicated urinary tract infections (cUTIs), including pyelonephritis, and complicated intra-abdominal infections (cIAIs). 6 The in vitro activity of ceftolozane/tazobactam extends to many drug-resistant Gram-negative pathogens, including most common ESBL-ENT and MDR Pseudomonas aeruginosa. 7, 8 Ceftolozane/tazobactam was studied in a large Phase 3 clinical programme [Assessment of the Safety Profile and Efficacy of Ceftolozane/Tazobactam (ASPECT)] in patients with cIAI or cUTI. In ASPECT-cIAI, ceftolozane/tazobactam plus metronidazole was non-inferior to meropenem, and in ASPECT-cUTI, ceftolozane/tazobactam demonstrated efficacy superior to that of high-dose levofloxacin. 9, 10 This analysis aimed to evaluate the characteristics and outcomes of patients infected with ESBL-ENT in the ASPECT trials. 
Methods

Study design and participants
These were randomized (1:1 ratio), double-blind, Phase 3 non-inferiority trials. 9, 10 In ASPECT-cUTI (NCT01345929/NCT01345955), adult patients (≥18 years) with cUTI, including pyelonephritis, received intravenous ceftolozane/tazobactam (1.5 g) every 8 h or levofloxacin (750 mg) once daily for 7 days. In ASPECT-cIAI (NCT01445665/NCT01445678), adults with cIAI necessitating surgical intervention received intravenous ceftolozane/tazobactam (1.5 g) plus metronidazole (500 mg) every 8 h or meropenem (1 g) every 8 h for 4 -14 days.
Ethics
Trials were approved by relevant regulatory agencies and local institutional review boards and were conducted in accordance with the International Conference on Harmonisation/Good Clinical Practice guidelines and the principles of the Declaration of Helsinki. All patients provided written informed consent.
Microbiological assessments
ESBL-phenotype ENT were identified from baseline urinary/intra-abdominal specimens per the following criteria: MIC ≥2 mg/L for a thirdgeneration cephalosporin or meropenem or MIC increase of ≥3 dilutions when combined with clavulanic acid. Isolates were characterized for genes encoding ESBL enzymes CTX-M groups 1, 2, 8 +25 and 9, TEM and SHV, carbapenemases and oxacillinases.
Susceptibility testing with ceftolozane/tazobactam and comparator antibiotics was performed using a CLSI broth microdilution method (at a fixed 4 mg/L concentration of tazobactam) at a central laboratory. Interpretation of results utilized CLSI/EUCAST breakpoints for comparator antibiotics 11, 12 and US FDA/EUCAST breakpoints for ceftolozane/tazobactam (≤2 and ≤1 mg/L, respectively). 6, 13 See the Supplementary data available at JAC Online for microbiological assessment details.
Endpoints and statistical analysis
Efficacy outcomes were clinical cure and microbiological eradication at the test-of-cure (TOC) visit in microbiologically evaluable (ME) patients with ESBL-ENT (pre-specified as a secondary endpoint in ASPECT-cIAI and supportive analysis in ASPECT-cUTI). The TOC visit was 5-9 days post-therapy in ASPECT-cUTI and 24-32 days from the start of therapy in ASPECT-cIAI. ME patients required receipt of study drug, a baseline infecting pathogen (regardless of susceptibility to study drug), adherence to the protocol and an outcome assessment of cure or failure at TOC. Clinical cure was defined as complete resolution/significant improvement of the signs and symptoms of the index infection, with no additional antibiotics (or surgical intervention for cIAI). In ASPECT-cUTI, microbiological eradication was defined as a TOC urine culture with ,10 4 cfu/mL of the baseline uropathogen. On-therapy/ post-therapy cultures are not routinely collected in patients with cIAI, thus, microbiological outcome was defined as presumed eradication (absence of material to culture in a patient assessed as a clinical cure at TOC). Descriptive statistics were used to summarize the microbiological susceptibility, and clinical and microbiological outcomes. The pooled clinical and microbiological outcomes were compared between ceftolozane/tazobactam and comparator arms using the Miettinen and Nurminen x 2 method. Individual treatment arms were compared using Fisher's exact test.
Results
Patient disposition and baseline characteristics
In the pooled ME population, 150 of 1346 (11.1%) patients had genotypically verified baseline ESBL-ENT ( Figure S1 , available as Supplementary data at JAC Online). The majority of patients with ESBL-ENT had a higher median BMI and were significantly more likely to be aged ≥65 years old, with renal impairment, complicated lower UTI or an indwelling catheter (P, 0.05), than patients without ESBL-ENT (Table S1 ).
Microbiology
Of the 159 ESBL-ENT isolates identified from the ME population at baseline, most were E. coli (68.6%) or K. pneumoniae (18.9%); genotypes are reported in Table S2 . The most prevalent enzymes in both species were CTX-M-15 and most isolates produced multiple enzymes.
Overall (Figure 1 ). At the EUCAST breakpoint of ≤1 mg/L, susceptibility to ceftolozane/tazobactam was 88.1% for ESBL-E. coli and 36.7% for ESBL-K. pneumoniae.
Clinical outcomes
Clinical cure rates for patients with ESBL-ENT (including CTX-M-14/ 15) were consistently higher with ceftolozane/tazobactam than with comparators ( Figure S2) (Table S3) .
In ASPECT-cUTI, clinical failure occurred in nine patients. All eight patients with clinical failure of levofloxacin had a baseline pathogen resistant to levofloxacin (seven of eight with a CTX-M producer). The only ceftolozane/tazobactam-treated patient with clinical failure had a susceptible CTX-M-14-producing E. coli. In ASPECT-cIAI, four patients were clinical failures. Three clinical failures of meropenem therapy had meropenemsusceptible ENT expressing CTX-M-15 in combination with OXA-1/30, SHV-11 and/or TEM-1. The single ceftolozane/tazobactam clinical failure had a K. pneumoniae isolate expressing SHV-1 with a ceftolozane/tazobactam MIC of 64 mg/L and meropenem MIC of 8 mg/L.
Microbiological outcomes
Consistent with clinical response rates, microbiological eradication rates at the TOC visit were higher with ceftolozane/tazobactam than with comparators ( Figure S2 ). Microbiological eradication was achieved in 79.5% (62 of 78) patients treated with ceftolozane/tazobactam compared with 62.5% (45 of 72) treated with comparators (pooled analysis); the difference between groups was 17.0% (P ¼ 0.022).
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Discussion
Perhaps the greatest problem in managing drug-resistant infections today is the increased pressure to use last-line agents such as carbapenems, resulting in increased carbapenem resistance.
14 A potential advantage of BL/BLIs such as ceftolozane/ tazobactam, as an alternative to carbapenems for the treatment of ESBL producers, could be a reduction in selective antimicrobial pressure. 15 In this analysis of randomized, controlled trial (RCT) data from 150 patients, ceftolozane/tazobactam (1.5 g) administered every 8 h was effective in treating cUTI and cIAI caused by ESBL-ENT. The overall clinical cure rate for ceftolozane/tazobactam against ESBL-ENT was 97.4%; clinical cure rates were high regardless of the presence/absence of CTX-M-14/15-type ESBLs.
In vitro susceptibility testing showed that ceftolozane/tazobactam was at least 2-fold more potent (MIC 90 values) than most antibacterials tested against ESBL-ENT. Surveillance studies have consistently shown that many antimicrobials have reduced activity against K. pneumoniae compared with E. coli, including ESBL producers. 7, 8, 16 Despite decreased in vitro activity of ceftolozane/tazobactam against ESBL-K. pneumoniae relative to ESBL-E. coli in these studies, ceftolozane/tazobactam was associated with high clinical cure rates in patients with ESBL-K. pneumoniae. It has been shown in other studies that the therapeutic response in Gram-negative infections is not always correlated with pathogen MIC. 17 The theoretical rationale for the use of BL/BLI combinations for treating infections caused by ESBL producers derives from the fact that BLIs inhibit the vast majority of ESBLs. 2 However, clinical data are mixed, with some reports suggesting that empirical BL/BLIs The pooled ME population included patients who received study drug, had a baseline infecting pathogen regardless of susceptibility to study drug, adhered to the protocol and had an outcome assessment at the test-of-cure visit within the specified visit window.
b CLSI breakpoints applied for all antibiotics except ceftolozane/tazobactam, for which the US FDA breakpoint of 2/4/8 mg/L was applied.
are at least as effective as carbapenems for treating infections due to ESBL producers, 15 and others that BL-BLIs are significantly less effective than carbapenems. 18 It is important to emphasize that the ceftolozane/tazobactam results presented herein come from RCTs rather than observational studies.
In these Phase 3 data, higher in vitro activity against ESBL-ENT was noted with ceftolozane/tazobactam compared with piperacillin/tazobactam. Many common b-lactamases (SHV, TEM, OXA) hydrolyse piperacillin and, despite the protection afforded by the addition of tazobactam, susceptibility is reduced compared with WT strains. 19 Although ceftolozane is vulnerable to ESBLs, the addition of tazobactam lowers the MIC and broadens its activity against ESBL-E. coli and ESBL-K. pneumoniae.
20
This analysis on the use of ceftolozane/tazobactam in infections caused by ESBL-ENT is limited to patients with cUTI/cIAI. Data applicable to other infections such as bloodstream infection, pneumonia and meningitis are currently lacking, although a clinical trial in patients with ventilated pneumonia (NCT02070757) is ongoing. Although clinical cure rates in ESBL-K. pneumoniae were high, only 18 cases were analysed; results from susceptibility testing should therefore be used to guide clinical decisions.
In conclusion, we have presented results obtained from an a priori defined analysis of RCTs that showed an overall clinical cure rate of 97.4% with ceftolozane/tazobactam. This suggests that ceftolozane/tazobactam is an effective antibiotic option when treating cUTI or cIAI caused by ESBL-producing E. coli and K. pneumoniae, despite decreased in vitro activity. The combination may serve, in some instances, as a carbapenem-sparing treatment alternative.
